Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael F. Moyers is active.

Publication


Featured researches published by Michael F. Moyers.


International Journal of Radiation Oncology Biology Physics | 2001

Methodologies and tools for proton beam design for lung tumors

Michael F. Moyers; Daniel W. Miller; David A. Bush; Jerry D. Slater

PURPOSE Proton beams can potentially increase the dose delivered to lung tumors without increasing the dose to critical normal tissues because protons can be stopped before encountering the normal tissues. This potential can only be realized if tissue motion and planning uncertainties are correctly included during planning. This study evaluated several planning strategies to determine which method best provides adequate tumor coverage, minimal normal tissue irradiation, and simplicity of use. METHODS AND MATERIALS Proton beam treatment plans were generated using one or more of three different planning strategies. These strategies included designing apertures and boluses to the PTV, apertures to the PTV and boluses to the CTV, and aperture and bolus to the CTV. RESULTS The planning target volume as specified in ICRU Report 50 can be used only to design the lateral margins of beams, because the distal and proximal margins resulting from CT number uncertainty, beam range uncertainty, tissue motions, and setup uncertainties, are different than the lateral margins resulting from these same factors. The best strategy for target coverage with the planning tools available overirradiated some normal tissues unnecessarily. The available tools also made the planning of lung tumors difficult. CONCLUSIONS This study demonstrated that inclusion of target motion and setup uncertainties into a plan should be performed in the beam design step instead of creating new targets. New computerized treatment planning system tools suggested by this study will ease planning, facilitate abandonment of the PTV concept, improve conformance of the dose distribution to the target, and improve conformal avoidance of critical normal tissues.


Radiation Research | 2000

Acute Effects of Whole-Body Proton Irradiation on the Immune System of the Mouse

Eric H. Kajioka; Melba L. Andres; Jun Li; Xiao Wen Mao; Michael F. Moyers; Gregory A. Nelson; James M. Slater; Daila S. Gridley

Abstract Kajioka, E. H., Andres, M. L., Li, J., Mao, X. W., Moyers, M. F., Nelson, G. A., Slater, J. M. and Gridley, D. S. Acute Effects of Whole-Body Proton Irradiation on the Immune System of the Mouse. The acute effects of proton whole-body irradiation on the distribution and function of leukocyte populations in the spleen and blood were examined and compared to the effects of photons derived from a 60Co γ-ray source. Adult female C57BL/6 mice were exposed to a single dose (3 Gy at 0.4 Gy/min) of protons at spread-out Bragg peak (SOBP), protons at the distal entry (E) region, or γ rays and killed humanely at six different times thereafter. Specific differences were noted in the results, thereby suggesting that the kinetics of the response may be variable. However, the lack of significant differences in most assays at most times suggests that the RBE for both entry and peak regions of the Bragg curve was essentially 1.0 under the conditions of this study. The greatest immunodepression was observed at 4 days postexposure. Flow cytometry and mitogenic stimulation analyses of the spleen and peripheral blood demonstrated that lymphocyte populations differ in radiosensitivity, with B (CD19+) cells being most sensitive, T (CD3+) cells being moderately sensitive, and natural killer (NK1.1+) cells being most resistant. B lymphocytes showed the most rapid recovery. Comparison of the T-lymphocyte subsets showed that CD4+ T helper/inducer cells were more radiosensitive than the CD8+ T cytotoxic/suppressor cells. These findings should have an impact on future studies designed to maximize protection of normal tissue during and after proton-radiation exposure.


International Journal of Radiation Oncology Biology Physics | 1995

Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration : Treatment techniques and preliminary results

Leslie T. Yonemoto; Jerry D. Slater; Eric J. Friedrichsen; Lilia N. Loredo; Jeffrey Ing; John O. Archambeau; Sandra Teichman; Michael F. Moyers; Paul Blacharski; James M. Slater

PURPOSE Age-related macular degeneration is the prevalent etiology of subfoveal choroidal neovascularization (CNV). The only effective treatment is laser photocoagulation, which is associated with decreased visual acuity following treatment in most patients. This study assessed both the response of subfoveal CNV to proton beam irradiation and treatment-related morbidity. We evaluated preliminary results in patients treated with an initial dose of 8 Cobalt Gray Equivalents (CGE) using a relative biological effectiveness (RBE) of 1.1. METHODS AND MATERIALS Twenty-one patients with subfoveal CNV received proton irradiation to the central macula with a single fraction of 8 CGE; 19 were eligible for evaluation. Treatment-related morbidity was based on Radiation Therapy Oncology Group (RTOG) criteria; response was evaluated by Macular Photocoagulation Study (MPS) guidelines. Fluorescein angiography was performed; visual acuity, contrast sensitivity, and reading speed were measured at study entry and at 3-month intervals after treatment. Follow-up ranged from 6 to 15 months. RESULTS No measurable treatment-related morbidity was seen during or after treatment. Of 19 patients evaluated at 6 months, fluorescein angiography demonstrated treatment response in 10 (53%); 14 (74%) patients had improved or stable visual acuity. With a mean follow-up of 11.6 months, 11 (58%) patients have demonstrated improved or stable visual acuity. CONCLUSION A macular dose of 8 CGE yielded no measurable treatment morbidity in patients studied. Fluorescein angiography demonstrated that regressed or stabilized lesions were associated with improved visual acuity as compared with MPS results. In the next phase, a dose of 14 CGE in a single fraction will be used to further define the optimal dose fractionation schedule.


International Journal of Radiation Oncology Biology Physics | 1997

Proton therapy for pediatric cranial tumors: Preliminary report on treatment and disease-related morbidities

Bruce McAllister; John O. Archambeau; M.Connie Nguyen; Jerry D. Slater; Lilia N. Loredo; Reinhard W. Schulte; Ofelia Alvarez; Antranik A. Berdros; Thomas Kaleita; Michael F. Moyers; Daniel W. Miller; James M. Slater

PURPOSE Accelerated protons were used in an attempt to limit treatment-related morbidity in children with tumors in or near the developing brain, by reducing the integral dose to adjacent normal tissues. METHODS AND MATERIALS Children treated with protons at Loma Linda University Medical Center between August 1991 and December 1994 were analyzed retrospectively. Twenty-eight children, aged 1 to 18 years, were identified as at risk for brain injury from treatment. Medical records, physical examinations, and correspondence with patients, their parents, and referring physicians were analyzed. The investigators tabulated post-treatment changes in pre-treatment signs and symptoms and made judgments as to whether improvement, no change, or worsening related to disease or treatment had supervened. Magnetic resonance images were correlated with clinical findings and radiographic impressions were tabulated. RESULTS Follow-up ranged from 7 to 49 months (median 25 months). Four instances of treatment-related morbidity were identified. Forty-one instances of site-specific, disease-related morbidity were identified: 15 improved or resolved and 26 remained unchanged after treatment. Four patients had radiographic evidence of local failure. Three of these patients, including two with high-grade glioma, have died. CONCLUSION Early treatment-related morbidity associated with proton therapy is low. Tumor progression remains a problem when treating certain histologies such as high-grade glioma. Escalating the dose delivered to target volumes may benefit children with tumors associated with poor rates of local control. Long-term follow-up, including neurocognitive testing, is in progress to assess integral-dose effects on cognitive, behavioral and developmental outcomes in children with cranial tumors.


Medical Dosimetry | 2010

Ion Stopping Powers and CT Numbers

Michael F. Moyers; Milind Sardesai; Sean Sun; Daniel W. Miller

One of the advantages of ion beam therapy is the steep dose gradient produced near the ions range. Use of this advantage makes knowledge of the stopping powers for all materials through which the beam passes critical. Most treatment planning systems calculate dose distributions using depth dose data measured in water and an algorithm that converts the kilovoltage X-ray computed tomography (CT) number of a given material to its linear stopping power relative to water. Some materials present in kilovoltage scans of patients and simulation phantoms do not lie on the standard tissue conversion curve. The relative linear stopping powers (RLSPs) of 21 different tissue substitutes and positioning, registration, immobilization, and beamline materials were measured in beams of protons accelerated to energies of 155, 200, and 250 MeV; carbon ions accelerated to 290 MeV/n; and iron ions accelerated to 970 MeV/n. These same materials were scanned with both kilovoltage and megavoltage CT scanners to obtain their CT numbers. Measured RLSPs and CT numbers were compared with calculated and/or literature values. Relationships of RLSPs to physical densities, electronic densities, kilovoltage CT numbers, megavoltage CT numbers, and water equivalence values converted by a treatment planning system are given. Usage of CT numbers and substitution of measured values into treatment plans to provide accurate patient and phantom simulations are discussed.


Medical Physics | 2007

Leakage and scatter radiation from a double scattering based proton beamline

Michael F. Moyers; E.R. Benton; A Ghebremedhin; G. Coutrakon

Proton beams offer several advantages over conventional radiation techniques for treating cancer and other diseases. These advantages might be negated if the leakage and scatter radiation from the beamline and patient are too large. Although the leakage and scatter radiation for the double scattering proton beamlines at the Loma Linda University Proton Treatment Facility were measured during the acceptance testing that occurred in the early 1990s, recent discussions in the radiotherapy community have prompted a reinvestigation of this contribution to the dose equivalent a patient receives. The dose and dose equivalent delivered to a large phantom patient outside a primary proton field were determined using five methods: simulations using Monte Carlo calculations, measurements with silver halide film, measurements with ionization chambers, measurements with rem meters, and measurements with CR-39 plastic nuclear track detectors. The Monte Carlo dose distribution was calculated in a coronal plane through the simulated patient that coincided with the central axis of the beam. Measurements with the ionization chambers, rem meters, and plastic nuclear track detectors were made at multiple locations within the same coronal plane. Measurements with the film were done in a plane perpendicular to the central axis of the beam and coincident with the surface of the phantom patient. In general, agreement between the five methods was good, but there were some differences. Measurements and simulations also tended to be in agreement with the original acceptance testing measurements and results from similar facilities published in the literature. Simulations illustrated that most of the neutrons entering the patient are produced in the final patient-specific aperture and precollimator just upstream of the aperture, not in the scattering system. These new results confirm that the dose equivalents received by patients outside the primary proton field from primary particles that leak through the nozzle are below the accepted standards for x-ray and electron beams. The total dose equivalent outside of the field is similar to that received by patients undergoing treatments with intensity modulated x-ray therapy. At the center of a patient for a whole course of treatment, the dose equivalent is comparable to that delivered by a single whole-body XCT scan.


Radiation Research | 2001

Response of Thyroid Follicular Cells to Gamma Irradiation Compared to Proton Irradiation. I. Initial Characterization of DNA Damage, Micronucleus Formation, Apoptosis, Cell Survival, and Cell Cycle Phase Redistribution

Lora M. Green; D. K. Murray; D. T. Tran; A. M. Bant; Gayane A. Kazarians; Michael F. Moyers; Gregory A. Nelson

Abstract Green, L. M., Murray, D. K., Tran, D. T., Bant, A. M., Kazarians, G., Moyers, M. F. and Nelson, G. A. Response of Thyroid Follicular Cells to Gamma Irradiation Compared to Proton Irradiation. I. Initial Characterization of DNA Damage, Micronucleus Formation, Apoptosis, Cell Survival, and Cell Cycle Phase Redistribution. The RBE of protons has been assumed to be equivalent to that of photons. The objective of this study was to determine whether radiation-induced DNA and chromosome damage, apoptosis, cell killing and cell cycling in organized epithelial cells was influenced by radiation quality. Thyroid-stimulating hormone-dependent Fischer rat thyroid cells, established as follicles, were exposed to γ rays or proton beams delivered acutely over a range of physical doses. Gamma-irradiated cells were able to repair DNA damage relatively rapidly so that by 1 h postirradiation they had approximately 20% fewer exposed 3′ ends than their counterparts that had been irradiated with proton beams. The persistence of free ends of DNA in the samples irradiated with the proton beam implies that either more initial breaks or a quantitatively different type of damage had occurred. These results were further supported by an increased frequency of chromosomal damage as measured by the presence of micronuclei. Proton-beam irradiation induced micronuclei at a rate of 2.4% per gray, which at 12 Gy translated to 40% more micronuclei than in comparable γ-irradiated cultures. The higher rate of micronucleus formation and the presence of larger micronuclei in proton-irradiated cells was further evidence that a qualitatively more severe class of damage had been induced than was induced by γ rays. Differences in the type of damage produced were detected in the apoptosis assay, wherein a significant lag in the induction of apoptosis occurred after γ irradiation that did not occur with protons. The more immediate expression of apoptotic cells in the cultures irradiated with the proton beam suggests that the damage inflicted was more severe. Alternatively, the cell cycle checkpoint mechanisms required for recovery from such damage might not have been invoked. Differences based on radiation quality were also evident in the α components of cell survival curves (0.05 Gy−1 for γ rays, 0.12 Gy−1 for protons), which suggests that the higher level of survival of γ-irradiated cells could be attributed to the persistence of nonlethally irradiated thyrocytes and/or the capacity to repair damage more effectively than cells exposed to equal physical doses of protons. The final assessment in this study was radiation-induced cell cycle phase redistribution. Gamma rays and protons produced a similar dose-dependent redistribution toward a predominantly G2-phase population. From our cumulative results, it seems likely that a majority of the proton-irradiated cells would not continue to divide. In conclusion, these findings suggest that there are quantitative and qualitative differences in the biological effects of proton beams and γ rays. These differences could be due to structured energy deposition from the tracks of primary protons and the associated high-LET secondary particles produced in the targets. The results suggest that a simple dose-equivalent approach to dosimetry may be inadequate to compare the biological responses of cells to photons and protons.


Physics in Medicine and Biology | 1999

Dosimetry techniques for narrow proton beam radiosurgery

Stanislav Vatnitsky; Daniel W. Miller; Michael F. Moyers; Richard P. Levy; Reinhard W. Schulte; Jerry D. Slater; James M. Slater

Characterization of narrow beams used in proton stereotactic radiosurgery (PSRS) requires special efforts, since the use of finite size detectors can lead to distortion of the measured dose distributions. Central axis depth doses, lateral profiles and field size dependence factors are the most important beam characteristics to be determined prior to dosimetry calculations and beam modelling for PSRS. In this paper we report recommendations for practical dosimetry techniques which were developed from a comparison of beam characteristics determined with a variety of radiation detectors for 126 and 155 MeV narrow proton beams shaped with 2-30 mm circular brass collimators. These detectors included small-volume ionization chambers, a diamond detector, an Hi-p Si diode, TLD cubes, radiographic and radiochromic films. We found that both types of film are suitable for profile measurements in narrow beams. Good agreement between depth dose distributions measured with ionization chambers, diamond and diode detectors was demonstrated in beams with diameters of 20-30 mm. The diode detector can be used in smaller beams, down to 5 mm diameter. For beams with diameters less than 5 mm, reliable depth dose data may be obtained only with radiochromic film. The tested ionization chambers are appropriate for calibration of beams with diameters of 20-30 mm. TLD cubes and diamond detectors are useful to determine relative dose in beams with diameters of 10-20 mm. Field size factors for smaller beams should be obtained with diode and radiochromic film. We conclude that dosimetry characterization of proton beams down to several millimetres in diameter can be performed using the described procedures.


Radiotherapy and Oncology | 1996

Proton dosimetry intercomparison

Stanislav Vatnitsky; J Siebers; Daniel W. Miller; Michael F. Moyers; M Schaefer; D. T. L. Jones; Stefaan Vynckier; Y Hayakawa; S Delacroix; Ulf Isacsson; Joakim Medin; A Kacperek; Antony Lomax; Adolf Coray; H Kluge; J Heese; Lynn Verhey; Inder K. Daftari; K Gall; G Lam; T Beck; Günther H. Hartmann

BACKGROUND AND PURPOSE Methods for determining absorbed dose in clinical proton beams are based on dosimetry protocols provided by the AAPM and the ECHED. Both groups recommend the use of air-filled ionization chambers calibrated in terms of exposure or air kerma in a 60Co beam when a calorimeter or Faraday cup dosimeter is not available. The set of input data used in the AAPM and the ECHED protocols, especially proton stopping powers and w-value is different. In order to verify inter-institutional uniformity of proton beam calibration, the AAPM and the ECHED recommend periodic dosimetry intercomparisons. In this paper we report the results of an international proton dosimetry intercomparison which was held at Loma Linda University Medical Center. The goal of the intercomparison was two-fold: first, to estimate the consistency of absorbed dose delivered to patients among the participating facilities, and second, to evaluate the differences in absorbed dose determination due to differences in 60Co-based ionization chamber calibration protocols. MATERIALS AND METHODS Thirteen institutions participated in an international proton dosimetry intercomparison. The measurements were performed in a 15-cm square field at a depth of 10 cm in both an unmodulated beam (nominal accelerator energy of 250 MeV) and a 6-cm modulated beam (nominal accelerator energy of 155 MeV), and also in a circular field of diameter 2.6 cm at a depth of 1.14 cm in a beam with 2.4 cm modulation (nominal accelerator energy of 100 MeV). RESULTS The results of the intercomparison have shown that using ionization chambers with 60Co calibration factors traceable to standard laboratories, and institution-specific conversion factors and dose protocols, the absorbed dose specified to the patient would fall within 3% of the mean value. A single measurement using an ionization chamber with a proton chamber factor determined with a Faraday cup calibration differed from the mean by 8%. CONCLUSION The adoption of a single ionization chamber dosimetry protocol and uniform conversion factors will establish agreement on proton absorbed dose to approximately 1.5%, consistent with that which has been observed in high-energy photon and electron dosimetry.


Medical Physics | 1995

Application of solid state detectors for dosimetry of therapeutic proton beams

Stanislav Vatnitsky; Daniel W. Miller; J Siebers; Michael F. Moyers

A PTW Riga diamond detector and LiF TLDs have been evaluated for use in proton beam dosimetry by comparing results of proton beam calibration with those obtained using thimble ionization chambers. The thimble ionization chambers were calibrated in terms of exposure while the TLDs and diamond detector were calibrated in terms of absorbed dose in a 60Co beam. Absorbed doses to muscle in proton beams for ionization chambers were derived using the TG 20 charged particle protocol. Absorbed doses to muscle for solid state detectors were derived using absorbed dose proton beam quality correction factors. Differences between the derived doses for ionization chambers and solid state detectors were found to be within the uncertainties of measurements: 4.5% for ionization chambers and 5% for solid state detectors.

Collaboration


Dive into the Michael F. Moyers's collaboration.

Top Co-Authors

Avatar

Daniel W. Miller

Loma Linda University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jerry D. Slater

Loma Linda University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John O. Archambeau

Loma Linda University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Stanislav Vatnitsky

Loma Linda University Medical Center

View shared research outputs
Top Co-Authors

Avatar

David A. Lesyna

Loma Linda University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D Followill

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

G. Coutrakon

Northern Illinois University

View shared research outputs
Researchain Logo
Decentralizing Knowledge